Shots:

• Therachon gains exclusive commercialization and development rights to apraglutide- initially developed by Ferring Pharma and was exclusively licensed by GLyPharma in 2012. Novo Holdings to fund the transaction with $60M
• The focus of the agreement is to improve QoL by providing novel and efficacious therapies for rare conditions including short bowel syndrome(SBS) and rare gastrointestinal diseases
• Apraglutide (FE 203799) is a qw synthetic GLP-2 analog- completed its P-I clinical trial demonstrated superior PK and currently evaluated in P-II for SBS

Ref: Therachon| Image: Sustain Ability